Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 856.00K | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -408.21M | -390.45M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -258.57M | -300.94M | -144.72M | -314.84M | -199.02M | -209.24M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 4.27M | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 129.00M | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.87B | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -313.25M | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -311.15M | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 1.62B | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -72.54M | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$31.14B | 34.99 | 27.37% | ― | 2.57% | 18.79% | |
54 Neutral | HK$13.69B | -48.42 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$8.96B | -15.59 | -42.46% | ― | 1219.19% | 25.15% | |
44 Neutral | HK$2.40B | -3.40 | -129.05% | ― | ― | -18.99% | |
40 Underperform | HK$8.66B | -41.39 | -21.42% | ― | 240.05% | -140.09% |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma has reported positive topline data from a Phase III open-label, multicenter study in China evaluating its first-in-class, once-daily oral fatty acid synthase inhibitor denifanstat (ASC40) in 240 patients with moderate-to-severe acne vulgaris, showing a favorable long-term safety and tolerability profile over 40 weeks with mostly mild to moderate treatment-emergent adverse events and no drug-related serious or grade 3/4 adverse events or deaths. Combined with previously disclosed Phase III placebo-controlled efficacy data, these results strengthen the case for denifanstat as a potentially breakthrough acne therapy that directly targets sebum overproduction and inflammation, and follow the recent acceptance of the drug’s New Drug Application by China’s National Medical Products Administration, potentially enhancing Ascletis’s dermatology pipeline value and competitive positioning in the Chinese acne treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma has begun dosing the first participants in a 13-week, randomized Phase II trial in the U.S. to evaluate its oral small molecule GLP-1 receptor agonist ASC30 for the treatment of type 2 diabetes, with topline data expected in the third quarter of 2026. The move follows a recently completed 13-week U.S. Phase II obesity study, in which once-daily ASC30 tablets achieved up to 7.7% placebo-adjusted weight loss with favorable gastrointestinal tolerability and a low discontinuation rate, reinforcing the drug’s potential best-in-class profile and supporting Ascletis’s strategic push into the sizeable diabetes market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma has selected ASC37, a next-generation, once‑monthly, subcutaneously administered GLP‑1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for obesity and plans to file an Investigational New Drug application with the U.S. FDA in the second quarter of 2026, with Phase I initiation targeted for the second half of 2026. Discovered and engineered in-house using Ascletis’ AI-enabled and ultra‑long‑acting technologies, ASC37 has shown markedly higher in vitro potency and a roughly 17‑day observed half-life in non-human primate studies—about seven times longer than retatrutide—supporting monthly dosing and potential manufacturing scalability advantages, and is also being positioned for use alone or in combination with the company’s other once‑monthly peptide candidates to address obesity, diabetes and broader cardio‑metabolic diseases, bolstering Ascletis’ ambitions in the competitive metabolic therapeutics market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma has received U.S. FDA Investigational New Drug clearance to launch a 13-week Phase II clinical trial of its oral small molecule GLP-1 receptor agonist ASC30 in participants with type 2 diabetes, with enrollment of about 100 U.S. patients expected to start in the first quarter of 2026. The randomized, double-blind, placebo-controlled, multi-centre study will assess changes in HbA1c as the primary endpoint, alongside fasting blood glucose, body weight, and safety, positioning ASC30 as a potential entrant in the sizeable diabetes treatment market. The decision follows a completed 13-week U.S. Phase II trial in obesity and overweight patients where ASC30 achieved up to 7.7% placebo-adjusted weight loss with favourable gastrointestinal tolerability and low discontinuation rates, reinforcing Ascletis’ bid to compete in the increasingly crowded GLP-1 space and potentially broaden its presence in global metabolic disease therapeutics.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced an increase in its share repurchase program from HK$300 million to HK$500 million, citing the undervaluation of its stock and significant recent achievements in drug development. The company aims to enhance shareholder value and demonstrate confidence in its long-term growth prospects, with the repurchase funded by internal resources and conducted in compliance with relevant regulations.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced positive topline results from its U.S. Phase I study of ASC50, an oral small molecule IL-17 inhibitor. The study demonstrated that ASC50 is safe, well-tolerated, and exhibits a dose-proportional pharmacokinetic profile, supporting once-daily or potentially once-weekly dosing. The drug showed strong target engagement and is progressing to the next phase of clinical development for treating mild to moderate plaque psoriasis. These findings highlight ASC50’s potential as a best-in-class treatment option, leveraging Ascletis’s AI-assisted drug discovery technology.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that the China National Medical Products Administration has accepted its New Drug Application for denifanstat (ASC40), a first-in-class fatty acid synthase inhibitor for treating moderate-to-severe acne vulgaris. This acceptance marks a significant milestone for Ascletis as it moves closer to commercializing denifanstat, which has shown promising results in Phase III trials, demonstrating significant efficacy and a favorable safety profile.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced positive results from its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for obesity treatment. The study demonstrated significant weight loss and improved gastrointestinal tolerability compared to placebo, with no severe adverse events reported. These findings suggest a potential best-in-class profile for ASC30, positioning Ascletis favorably in the obesity treatment market as they plan to advance to Phase III trials.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the selection of its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, for clinical development. This drug candidate, developed using Ascletis’ proprietary technologies, has shown significantly higher bioavailability and potency compared to existing formulations in non-human primate studies. The company plans to submit an Investigational New Drug Application to the U.S. FDA in 2026, marking a significant step in addressing unmet needs in obesity treatment and strengthening Ascletis’ position in the pharmaceutical industry.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the co-formulation of ASC36, an amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist, both designed for once-monthly subcutaneous administration. The co-formulation demonstrated significant body weight reduction in preclinical studies and showed excellent stability, supporting its potential as a treatment for obesity. Ascletis plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, marking a significant step in its clinical development pipeline.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising results from its Phase Ib studies of ASC30, both as an oral tablet and a subcutaneous injection, along with a preclinical study of a combination therapy involving ASC31 and ASC47. The oral tablet showed up to a 6.5% placebo-adjusted mean body weight reduction, with mild-to-moderate gastrointestinal adverse events, while the injection demonstrated an extended half-life supporting monthly and quarterly dosing schedules. These findings highlight the efficacy and safety of Ascletis’ obesity treatments and reinforce the company’s competitive positioning in the obesity drug market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.